Avatropexa can promote platelet production and is reliable in the treatment of thrombocytopenia. The mechanism of action, indications, adverse effects and contraindications are described below. 1. Mechanism of action: Avastopar is a new thrombopoietin receptor agonist, which can stimulate the proliferation and differentiation of megakaryocytes in the bone marrow, thus increasing platelet production. This drug can be used in the treatment of primary immune thrombocytopenia. 2. Indications: primary immune thrombocytopenia, etc. 3. Adverse reactions and contraindications: the main target of thrombopoietin receptor agonists are in the megakaryocytes, although there is a certain degree of efficacy, but not 100% effective, do not blindly overuse. Headache and dizziness are the main adverse effects of this drug. It is contraindicated in women during pregnancy. Avatropex, needs to be used regularly under the supervision of a doctor.